- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2007.
-
- Dec.20.2007
- Ono Enters into License Agreement with Nissan Chemical for New Therapeutic Agent for Thrombocytopenia(61 KB)
-
- Dec.12.2007
- Announcement of JNDA Submission in Japan for SITAGLIPTIN,a New Oral Treatment of Type II Diabetes(29 KB)
-
- Nov.15.2007
- Ono Enters into Service Agreement with Nissin for Use of New Carcinogenicity Evaluation System, Developed by Nissin, for Pharmaceutical Compounds(61 KB)
-
- Nov.08.2007
- Revisions of Full Year Business Forecasts for FY 2007(78 KB)
-
- Nov.05.2007
- Ono Enteres Into New Drug Discovery Agreement on Kinases with Locus Pharmaceuticals, Inc.(78 KB)
-
- Oct.30.2007
- Initiation of Development of “ONO-4538/MDX-1106“, Fully Human Anti-PD-1 Antibody for Hepatitis C in US(19 KB)
-
- Oct.11.2007
- Announcement on Completion of Acquisition of the Company's Own Shares(61 KB)
-
- Sep.28.2007
- Exelon® patch receives European Union approval, the first skin patch therapy to treat Alzheimer's disease(98 KB)
-
- Aug.06.2007
- Ono Enters into License Agreement with CeNeS Limited - New Intravenous Anaesthetic -(23 KB)
-
- Aug.06.2007
- Announcement on Acquisition of the Company's Own Shares(62 KB)
-
- Jul.23.2007
- Novartis Receives First Worldwide Approval in US for Exelon Patch, the First and Only Skin Patch for the Treatment of Alzheimer's Disease(208 KB)
-
- Jul.10.2007
- Novartis Receives First Worldwide Approval in US for Exelon Patch, the First and Only Skin Patch for the Treatment of Alzheimer's Disease(155 KB)
-
- Jul.05.2007
- New Data Released at ADA Showed that Initial Combination Therapy with sitagliptin and Metformin Led to Significant Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes (Second Report)(75 KB)
-
- Jul.02.2007
- Data Released at ADA showed efficacy in the Investigational use of a new oral medicine for type 2 diabetes, sitagliptin, and other medicine as Initial Combination Therapy (First Report)(73 KB)
-
- Jun.28.2007
- Resolutions at the 59th Annual Shareholders Meeting(60 KB)
-
- Jun.20.2007
- The Company Views and Policy on the Decrease in Number of Shares in One Trading Unit(50 KB)
-
- Jun.11.2007
- Launch of Staybla® Tablets 0.1mg, a Drug for Overactive Bladder(61 KB)
-
- May.14.2007
- Revision on Compensation for Members of the Board of Directors(50 KB)
-
- May.14.2007
- The Company's Thoughts on the Shareholder Proposal(65 KB)
-
- Apr.18.2007
- Announcement of Approval of Staybla®Tablets 0.1mg, a Drug for Overactive Bladder(53 KB)
-
- Apr.10.2007
- Regarding Today's Media Report(52 KB)
-
- Apr.05.2007
- Merck & Co, Inc. (Whitehouse Station, New Jersey, USA) Announced Approval of SITAGLIPTIN, a New Oral Treatment of Diabetes, in the European Union(113 KB)
-
- Mar.26.2007
- Announcement on Completion of Acquisition of the Company's Own Shares(61 KB)
-
- Mar.26.2007
- Announcement on Cancellation of the Company's Own Shares(59 KB)
-
- Feb.27.2007
- Announcement of Establishment of Strategic Alliance Headquarters(62 KB)
-
- Feb.27.2007
- Ono resolved increase in dividends projected for the fiscal year 2006(ending on March 31st,2007)(146 KB)